Teduglutide
Aliases: Gattex · Revestive
Last verified: 2026-09-23
The short version
A GLP-2 analogue — approved for short-bowel syndrome: increases absorption and reduces parenteral-nutrition dependence.
Identity & type
- Molecular type
- analog
- Origin
- A GLP-2 analogue — approved for short-bowel syndrome: increases absorption and reduces parenteral-nutrition dependence.
Mechanism of action
GLP-2R agonism → villus/crypt growth, improved gut barrier and absorption.
Dosing & routes
Official / clinical context
Approved drug — indications, dosing and warnings are defined by the official label. 0.05 mg/kg SC daily.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
0.05 mg/kg SC daily. Gattex: in short-bowel syndrome significantly reduces parenteral-nutrition needs — patients gain independence from infusions.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
Gattex: in short-bowel syndrome significantly reduces parenteral-nutrition needs — patients gain independence from infusions.
Protocol — official vs community
Official / label
Gattex/Revestive, for short-bowel syndrome with dependence on parenteral nutrition (adults; pediatric approval exists in some markets): 0.05 mg/kg SC once daily.
Duration: Chronic. STEPS program: ~63% of patients achieved ≥20% reduction in parenteral-nutrition volume, and some weaned off entirely.
GLP-2R agonism regrows villus mass and improves absorption. Colonoscopy before starting and periodically thereafter per label, because trophic gut signaling could accelerate occult neoplasia.
Community (anecdotal)
No meaningful community use — specialty intestinal-rehabilitation drug with REMS-style distribution in the US.
- Cycle:
- —
- Break:
- —
Off-label IBD interest exists in the literature but no self-directed protocol has formed around it.
Human evidence
STEPS program: 63% of patients cut PN ≥20%; off-label interest in IBD.
Preclinical evidence
The preclinical phase was completed and submitted to regulators as part of registration; pharmacology and toxicology details are part of the official label.
Known risks
- Abdominal pain, stoma complications; risk of accelerating polyp/tumor growth (colonoscopy monitoring).characterized
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Real-world data outside controlled trials